Compare AbCellera Biologics Inc (ABCL) vs Oklo Inc (OKLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Oklo Inc — how do they compare? AbCellera Biologics Inc trades at $7.22 (market cap $2.35B), while Oklo Inc trades at $47.16 (market cap $8.33B). The key difference: Oklo Inc is far larger — about 3.5× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | OKLO | |
|---|---|---|
Market Cap | $2.35B | $8.33B |
Sector | Health | Technology |
52-Week High | $8.12 | $174.14 |
52-Week Low | $2.78 | $45.58 |
Enterprise Value | $1.99B | $6.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
OKLO trades at $51.84, down 0.99% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $105.66 million for 2025 and negative cash flow from operations. Recent positive developments include DOE safety approval for its Groves Isotope Test Reactor and strategic acquisitions to accelerate reactor development.
Analyst consensus remains strongly bullish with a $96 price target, but execution risks and sustained losses pose challenges. The stock's outlook hinges on successful reactor deployment and achieving profitability amid high cash burn. Investors should weigh the high growth potential against substantial operational and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
